Table 5 Cox proportional hazards univariate and multivariate analysis of progression after primary transurethral resection for T1 bladder carcinoma in the Southeast care region in Sweden 1992–2001
From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
Univariate Hazard ratio (95% CI) | Multivariate Hazard ratio (95% CI) | p-value | |
|---|---|---|---|
LVI* | |||
No | 1.0 | 1.0 | |
Suspected | 1.01 (0.51–2.00) | 0.84 (0.42–1.68) | 0.70 |
Yes | 3.10 (1.48–6.49) | 3.84 (1.75–8.42) | 0.001 |
p16 | |||
Abnormal | 1.0 | 1.0 | |
Normal | 0.40 (0.23–0.74) | 0.37 (0.19–0.69) | 0.002 |
p21 | |||
Abnormal | 1.0 | 1.0 | |
Normal | 1.93 (0.77–4.86) | 1.39 (0.54–3.59) | 0.50 |
p53 | |||
Abnormal | 1.0 | 1.0 | |
Normal | 0.75 (0.42–1.35) | 1.54 (0.84–2.82) | 0.17 |
p53 mutation | |||
No | 1.0 | 1.0 | |
Yes | 1.51 (0.87–2.59) | 1.28 (0.73–2.23) | 0.38 |
MDM2 T/T | |||
No | 1.0 | 1.0 | |
Yes | 1.52 (0.89–2.62) | 1.75 (1.00–3.06) | 0.052 |
pRb | |||
Abnormal | 1.0 | 1.0 | |
Normal | 1.36 (0.70–2.65) | 1.58 (0.79–3.17) | 0.20 |